Intercept Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Intercept Pharmaceuticals's estimated annual revenue is currently $354.3M per year.
- Intercept Pharmaceuticals's estimated revenue per employee is $768,612
- Intercept Pharmaceuticals's total funding is $567.1M.
- Intercept Pharmaceuticals's current valuation is $524.8M. (January 2022)
Employee Data
- Intercept Pharmaceuticals has 461 Employees.
- Intercept Pharmaceuticals grew their employee count by -2% last year.
Intercept Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP | Reveal Email/Phone |
2 | CSO | Reveal Email/Phone |
3 | Chief Accounting Officer; Acting Chief Financial Officer & Treasurer | Reveal Email/Phone |
4 | VP, Head Total Rewards | Reveal Email/Phone |
5 | VP, Market Access | Reveal Email/Phone |
6 | VP, Clinical Development | Reveal Email/Phone |
7 | Head, U.S. Key Accounts, Gastroenterology and Hepatology | Reveal Email/Phone |
8 | SVP Corporate Affairs | Reveal Email/Phone |
9 | General Counsel | Reveal Email/Phone |
10 | Head Patient Advocacy | Reveal Email/Phone |
Intercept Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $12.3M | 61 | 7% | N/A | N/A |
#2 | $354.3M | 461 | -2% | $567.1M | N/A |
#3 | $377.1M | 1876 | -1% | N/A | N/A |
#4 | $7.8M | 39 | 8% | N/A | N/A |
#5 | $5.4M | 27 | 0% | N/A | N/A |
#6 | $45M | 224 | 6% | N/A | N/A |
#7 | $6.8M | 34 | -82% | N/A | N/A |
#8 | $9.2M | 46 | 12% | N/A | N/A |
#9 | N/A | 694 | 46% | N/A | N/A |
#10 | $15.5M | 77 | 5% | N/A | N/A |
What Is Intercept Pharmaceuticals?
New York City-based Intercept Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing small molecule drugs for the treatment of chronic liver and metabolic diseases. Since 2002, Intercept researchers have published extensively on the key role of the farnesoid X receptor (FXR) as a regulator of bile and cholesterol metabolism in the liver with preclinical data from numerous studies providing strong rationale for the advancement of FXR agonists as hepatoprotective therapeutics in chronic liver disease. The company intends to lead in the advancement of drug candidates acting on FXR and other bile acid receptors and is developing a pipeline of novel lead compounds for multiple indications.
keywords:Biotechnology, Healthcare
$567.1M
Total Funding
461
Number of Employees
$354.3M
Revenue (est)
-2%
Employee Growth %
$524.8M
Valuation
N/A
Accelerator
Intercept Pharmaceuticals News
Intercept currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks are Vertex Pharmaceuticals Incorporated VRTX and Voyager...
Intercept Pharmaceuticals Inc gets a 84 rank in the Biotechnology industry. Biotechnology is number 64 out of 148 industries. Overall Score - 60.
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Given Average Recommendation of Hold by Brokerages. Posted by admin on Apr 14th, 2022.
Intercept Pharmaceuticals November 2021 Debbie, Living with PBC Cautionary Note Regarding Forward-Looking Statements and Non-GAAP Financial Measures This presentation contains forward-looking statements, including, but not limited to, statements regarding the progress, timing and results o ...
Other Companies in New York
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $118.1M | 461 | 5% | N/A |
#2 | $155.6M | 461 | N/A | N/A |
#3 | $185M | 461 | 6% | N/A |
#4 | $86.4M | 461 | 7% | N/A |
#5 | $103.7M | 461 | 8% | N/A |